Blackrock Neurotech vs Neuralink
Side-by-side equity comparison for employees weighing offers at Blackrock Neurotech or Neuralink. Valuations, funding history, headcount growth, and secondary-market context.
| Blackrock Neurotech | Neuralink | |
|---|---|---|
| Latest valuation | Not publicly disclosed | $10B |
| Latest round | Series C | Series D |
| Round date | — | November 2024 |
| Total raised | $48M | $680M |
| Founded | 2008 | 2016 |
| Headquarters | Salt Lake City, UT | Fremont, CA |
| Employees | 178 | 628 |
| Employee YoY growth | +5% | +19% |
| Primary industry | Healthcare & Biotech | Healthcare & Biotech |
| Secondary-market price | — | — |
| Base-case equity multiple | — | 1x |
| Upside equity multiple | — | 1x |
| Lead investors | — | Founders Fund, GV (Google Ventures) |
| Status | private | private |
Overview
Blackrock Neurotech develops brain-computer interface (BCI) technology, manufacturing the Utah Array and other neural implants that enable paralyzed patients to control computers and robotic limbs with their thoughts.
Neuralink develops implantable brain-computer interfaces designed to enable people with paralysis to control digital devices with their thoughts.
Why we compare these
Neuralink appears on Sara's List 2024; Blackrock Neurotech is a direct competitor we track alongside it.
If you're evaluating offers at either one, the equity math depends on more than the headline valuation — dilution, strike price, time to liquidity, and concentration risk all matter. Use our equity compensation calculator and exit calculator to model your own numbers.